Friday, July 10, 2026

Drug profile · INN

ropivacaine

ropivacaine is a sodium channel alpha subunit blocker.

NMPA: clinical trials
Patents linked 0
Pipeline programs 24
News articles 0
Drug details — ropivacaine
Class
Route
Patents
0
Programs
24
Data quality
0.70